The DOI matches its Crossref record; 78 of the 78 references it cites were found in a registry or an index.
Newer antidepressants and the cytochrome P450 system
Abstract
OBJECTIVE: This review evaluates the in vitro and in vivo evidence for inhibition of cytochrome P450 enzymes by the newer antidepressants and provides clinical recommendations for avoiding and managing drug interactions. METHOD: The international literature on the cytochrome P450 system and related drug interactions from 1966 to 1995 was reviewed. In vitro studies, pharmacokinetic trials in human subjects, and case reports were assessed. RESULTS: The newer antidepressants each inhibit a different cluster of cytochrome P450 enzymes, which are of relevance to the potential for drug interactions. Cytochrome P450 1A2 is inhibited by fluvoxamine and is implicated in drug interactions with theophylline, clozapine, and others. Fluoxetine, norfluoxetine, sertraline, and paroxetine are potent in vitro inhibitors of cytochrome P450 2D6 and are capable of causing marked elevations in plasma desipramine and nortriptyline concentrations. Fluoxetine, sertraline, and fluvoxamine are believed to inhibit cytochrome P450 2C because of observed interactions with phenytoin, diazepam, and other drugs metabolized by these enzymes. Cytochrome P450 3A4 metabolizes terfenadine, astemizole, carbamazepine, alprazolam, triazolam, and other benzodiazepines. Plasma concentrations of these drugs have increased when they are administered with fluvoxamine, nefazodone, fluoxetine, and sertraline. CONCLUSIONS: The majority of the newer antidepressants are associated with a risk for clinically significant drug interactions. A rapidly growing body of literature provides evidence for a distinct profile of cytochrome P450 inhibition and drug interaction risks by individual antidepressants. These findings underscore the need for definitive in vivo interaction studies of plasma from phenotyped patients treated with clinically effective antidepressant doses of medication, for direct comparative clinical studies, and for studies assessing the utility of phenotyping in clinical practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Terfenadine-Ketoconazole Interaction: Pharmacokinetic and Electrocardiographic Consequences
Honig, P. K. (1993) · JAMA · doi:10.1001/jama.1993.03500120051025 · Cited by 664
Rettie, A. E., Korzekwa, K. R., Kunze, K. L., Lawrence, R. F., Eddy, A. C., Aoyama, T., Gelboin, H. V., Gonzalez, F. J., & Trager, W. F. (1992) · Chemical Research in Toxicology · doi:10.1021/tx00025a009 · Cited by 601
Evans, D. A., Mahgoub, A., Sloan, T. P., Idle, J. R., & Smith, R. L. (1980) · Journal of Medical Genetics · doi:10.1136/jmg.17.2.102 · Cited by 536
Crewe, H., Lennard, M., Tucker, G., Woods, F., & Haddock, R. (1992) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1992.tb04134.x · Cited by 469
Nakamura, K., Goto, F., Ray, W. A., McAllister, C. B., Jacqz, E., Wilkinson, G. R., & Branch, R. A. (1985) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1985.194 · Cited by 452
Human liver carbamazepine metabolism
Kerr, B. M., Thummel, K. E., Wurden, C. J., Klein, S. M., Kroetz, D. L., Gonzalez, F. J., & Levy, R. (1994) · Biochemical Pharmacology · doi:10.1016/0006-2952(94)90071-x · Cited by 433
Butler, M. A., Lang, N. P., Young, J. F., Caporaso, N. E., Vineis, P., Hayes, R. B., Teitel, C. H., Massengill, J. P., Lawsen, M. F., & Kadlubar, F. F. (1992) · Pharmacogenetics · doi:10.1097/00008571-199206000-00003 · Cited by 419
Fluvoxamine is a potent inhibitor of cytochrome P4501A2
Brøsen, K., Skjelbo, E., Rasmussen, B. B., Poulsen, H. E., & Loft, S. (1993) · Biochemical Pharmacology · doi:10.1016/0006-2952(93)90272-x · Cited by 374
The genetic polymorphism of debrisoquine/sparteine metabolism — Clinical aspects
Eichelbaum, M., & Gross, A. S. (1990) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(90)90025-w · Cited by 368
Evidence That CYP2C19 is the Major (S)-Mephenytoin 4'-Hydroxylase in Humans
Goldstein, J. A., Faletto, M. B., Romkes-Sparks, M., Sullivan, T., Kitareewan, S., Raucy, J. L., Lasker, J. M., & Ghanayem, B. I. (1994) · Biochemistry · doi:10.1021/bi00173a017 · Cited by 360
Cited by
Pharmacokinetics of selective serotonin reuptake inhibitors
Hiemke, C., & Härtter, S. (2000) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(99)00048-0 · Cited by 883
Summary of information on human CYP enzymes: human P450 metabolism data
Rendic, S. (2002) · Drug Metabolism Reviews · doi:10.1081/dmr-120001392 · Cited by 820
Update: Clinically Significant Cytochrome P‐450 Drug Interactions
Michalets, E. L. (1998) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.1998.tb03830.x · Cited by 597
First-Trimester Use of Selective Serotonin-Reuptake Inhibitors and the Risk of Birth Defects
Louik, C., Lin, A. E., Werler, M. M., Hernández-Díaz, S., & Mitchell, A. A. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067407 · Cited by 500
National Trends in Psychotropic Medication Polypharmacy in Office-Based Psychiatry
Mojtabai, R., & Olfson, M. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.175 · Cited by 479
“Furthermore, antidepressant-antipsychotic combinations are especially prone to adverse drug-drug interactions mainly because of the effects of antidepressants on the cytochrome P450 system.(49) For example, both fluoxetine and fluvoxamine significantly increase the serum level of concomitantly used clozapine.”
BackgroundSystematic Review and Guide to Selection of Selective Serotonin Reuptake Inhibitors
Edwards, J. G., & Anderson, I. (1999) · Drugs · doi:10.2165/00003495-199957040-00005 · Cited by 458
Sudden unexpected death in epilepsy: risk factors and potential pathomechanisms
Surges, R., Thijs, R. D., Tan, H. L., & Sander, J. W. (2009) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.118 · Cited by 431
Kirchheiner, J., Brøsen, K., Dahl, M. L., Gram, L. F., Kasper, S., Roots, I., Sjöqvist, F., Spina, E., & Brockmöller, J. (2001) · Acta Psychiatrica Scandinavica · doi:10.1034/j.1600-0447.2001.00299.x · Cited by 422
Baldessarini, R. J. (2013) · doi:10.1007/978-1-4614-3710-9 · Cited by 365
Spina, E., Santoro, V., & D'Arrigo, C. (2008) · Clinical Therapeutics · doi:10.1016/s0149-2918(08)80047-1 · Cited by 361
Inhibition and induction of human cytochrome P450 (CYP) enzymes
PELKONEN, O., MÄEENPÄEÄ, J., TAAVITSAINEN, P., RAUTIO, A., & RAUNIO, H. (1998) · Xenobiotica · doi:10.1080/004982598238886 · Cited by 358
Mechanisms of Clinically Relevant Drug Interactions Associated with Tacrolimus
Christians, U., Jacobsen, W., Benet, L. Z., & Lampen, A. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241110-00003 · Cited by 323
Pharmacogenetics of Psychotropic Drug Response
Malhotra, A. K., Murphy, G. M., & Kennedy, J. L. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.5.780 · Cited by 300
Depression in Epilepsy: Etiology, Phenomenology, and Treatment
Lambert, M. V., & Robertson, M. M. (1999) · Epilepsia · doi:10.1111/j.1528-1157.1999.tb00884.x · Cited by 293
Comorbidity of depression with other medical diseases in the elderly
Krishnan, K. R. R., Delong, M., Kraemer, H., Carney, R., Spiegel, D., Gordon, C., McDonald, W., Dew, M. A., Alexopoulos, G., Buckwalter, K., et al. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01472-5 · Cited by 290
Depression in patients with cardiac disease
Lespérance, F., & Frasure-Smith, N. (2000) · Journal of Psychosomatic Research · doi:10.1016/s0022-3999(99)00102-6 · Cited by 284
Ziedonis, D. M., & George, T. P. (1997) · Schizophrenia Bulletin · doi:10.1093/schbul/23.2.247 · Cited by 278
A review of the receptor-binding and pharmacokinetic properties of dopamine agonists
Kvernmo, T., Härtter, S., & Burger, E. (2006) · Clinical Therapeutics · doi:10.1016/j.clinthera.2006.08.004 · Cited by 277
Personalized medicine in psychiatry: problems and promises
Ozomaro, U., Wahlestedt, C., & Nemeroff, C. B. (2013) · BMC Medicine · doi:10.1186/1741-7015-11-132 · Cited by 270
Margolese, H. C., Malchy, L., Negrete, J. C., Tempier, R., & Gill, K. (2004) · Schizophrenia Research · doi:10.1016/s0920-9964(02)00523-6 · Cited by 267
Evidence-based pharmacotherapy for attention-deficit hyperactivity disorder
Biederman, J., Spencer, T., & Wilens, T. (2004) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145703003973 · Cited by 253
Assessment and treatment of depression in the cancer patient
Newport, D. J., & Nemeroff, C. B. (1998) · Journal of Psychosomatic Research · doi:10.1016/s0022-3999(98)00011-7 · Cited by 167
Self-citationDepression and coronary heart disease: A review for cardiologists
Carney, R. M., Freedland, K. E., Sheline, Y. I., & Weiss, E. S. (1997) · Clinical Cardiology · doi:10.1002/clc.4960200304 · Cited by 159
Benzodiazepines and anxiety disorders: a review for the practicing physician
Kaplan, E. M., & DuPont, R. L. (2005) · Current Medical Research and Opinion · doi:10.1185/030079905x48401 · Cited by 55
Markowitz, J. S., & DeVane, C. L. (2000) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200002000-00023 · Cited by 34
Self-citationThe geriatric population and psychiatric medication
Varma, S., Sareen, H., & Trivedi, J. (2010) · Mens Sana monographs · doi:10.4103/0973-1229.58818 · Cited by 27
Symptoms of delusion: the effects of discontinuation of low-dose venlafaxine
Koga, M., Kodaka, F., Miyata, H., & Nakayama, K. (2009) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2009.01433.x · Cited by 9
Selective serotonin reuptake inhibitors and withdrawal symptoms: a review of the literature
Therrien, F., & Markowitz, J. S. (1997) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/(sici)1099-1077(199707/08)12:4<309::aid-hup855>3.0.co;2-a
Metadata
- Venue
- American Journal of Psychiatry
- Published
- 1996-03-01
- Volume
- 153
- Issue
- 3
- Pages
- 311-320
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2416351818
- Cited by
- 482
- References
- 78
- FWCI
- 66.54
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.